Troglitazone,a PPAR-γ agonist,decreases LTC4 concentration in mononuclear cells in patients with asthma

Background asthma is an inflammatory disorder with multiple mediators involved in the inflammatory response. despite several attempts,no new anti-inflammatory drugs have been registered for asthma treatment for several years. however,thiazolidinediones,peroxisome proliferator-activated receptor agonists,have demonstrated some anti-inflammatory properties in various experimental settings. the aim of this study was to assess the influence of troglitazone on ltc4 and 15-hete concentrations. it also evaluates tnf-induced eotaxin synthesis in peripheral blood mononuclear cells from 14 patients with mild asthma and 13 healthy controls. methods pbmcs were isolated from the whole blood of the asthmatics and healthy subjects and pretreated with 0.1,1 or 10 μm of troglitazone. the cells were then exposed to 10−6 m calcium jonophore or 10 ng/ml tnf. the production and release of ltc4,15-hete and eotaxin were then assessed. results troglitazone caused a dose-dependent inhibition in ltc4 synthesis in both asthmatics and healthy subjects. troglitazone did not influence 15-hete or eotaxin production in either asthmatic patients or in healthy individuals. conclusion due to its inhibition of ltc4 synthesis,troglitazone therapy is an interesting potential therapeutic approach in asthma and other ltc4 related inflammatory disorders. © 2017 institute of pharmacology,polish academy of sciences